Biology of Autism — Intervention Logic

WAVE 1 — PLUG THE LEAK

Stop the NAD⁺ hemorrhage before refilling the tank.
Targets: PARP hyperactivation (niacinamide), CD38-mediated NAD⁺ drain (luteolin/apigenin), LPS supply line (S. boulardii, gut barrier repair), oxidative stress (NAC, sulforaphane).
Rationale: adding NAD⁺ precursors into an unrepaired system is like filling a bucket with holes.

WAVE 2 — FILL THE TANK

Restore functional NAD⁺ sufficiency and activate SIRT1.
Targets: NAD⁺ repletion (NMN/NR), SIRT1 activation (resveratrol/pterostilbene), mitochondrial biogenesis (CoQ10, Mg), SST brake release (forskolin/cAMP support), circadian repair (melatonin).
Rationale: SIRT1 cannot function without its cofactor; the four downstream outputs remain offline until NAD⁺ is restored.

WAVE 3 — REBUILD THE ARCHITECTURE

Support synaptogenesis and circuit maturation once inflammatory load is reduced.
Targets: Hevin/SPARC rebalance (luteolin — SPARC suppression), glypican/AMPA support (omega-3), CREB/BDNF restoration (sodium butyrate, L-theanine), microglial reset (fisetin), gut-brain rhythm (C. butyricum).
Rationale: architectural repair cannot occur while glial cells remain reactive and CREB is suppressed.

NAD⁺ Drain Sources (Wave 1 priority): Three enzymes compete with SIRT1 for NAD⁺ under inflammatory conditions: PARP (DNA repair hyperactivation → niacinamide targets this), CD38 (immune activation NADase → luteolin and apigenin reduce CD38 expression), and SARM1 (axonal degeneration pathway). Addressing all three drains simultaneously maximizes the NAD⁺ available for SIRT1 reactivation in Wave 2.

● Human RCT Evidence ● Early Human Evidence ● Animal / Preclinical ● Mechanistically Plausible

Clinician & Researcher View — Full Mechanistic Detail

Cascade Node Target	Compound / Intervention	Mechanism of Action	Typical Range / Notes	Evidence Tier
Upstream Immune / Neuroinflammation	IVIG / IMIG Intravenous / Intramuscular Immunoglobulin	The furthest upstream intervention in this framework. Pooled human IgG suppresses IFN-γ, TNF-α, and IL-6 — the cytokines that drive IDO1 upregulation — before the kynurenine pathway is activated. Addresses the inflammatory driver rather than its downstream consequences. Meta-analysis of 27 IVIG studies in ASD (Rossignol & Frye, 2021) demonstrated large effect sizes for irritability (dʼ=0.87) and total aberrant behaviour (dʼ=0.80). First published IMIG case report in ASD (Fourie & Armstrong, 2024) showed positive parental-rated outcomes in 6 of 7 children with level 2 ASD. See Biology of Autism — Immunoglobulin Therapy for the full mechanistic argument, IVIG vs IMIG pharmacokinetics, and trial context.	IVIG: 0.4–2 g/kg IV; requires infusion centre, medical supervision. High cost limits access. IMIG: 0.2 mL/kg IM monthly (Fourie protocol, 16% IgG); outpatient administration. Materials cost approximately $50 per treatment (NBI Intragam, South Africa — repricing from prior below-cost supply; comparable global product Beriglobin at $80 per dose). A fraction of IVIG cost at $10,000–$25,000 per infusion. ⚠ Specialist Oversight Required: Immunoglobulin therapy requires immune workup (IgG subclasses, cytokine panel, autoantibody screen) before initiation. Not appropriate without documented immune dysregulation and specialist involvement. IMIG use in ASD is investigational — not approved for this indication.	Human Case Series Meta-Analysis (IVIG)
NAD¹ Restoration	NMN / NR Nicotinamide Mononucleotide / Riboside	Direct NAD¹ precursors; restore functional NAD¹ sufficiency reduced by IDO1/kynurenine pathway diversion under chronic inflammation — quinolinic acid accumulates faster than QPRT converts it, creating NAD¹ insufficiency rather than classical depletion. Supports mitochondrial biogenesis via PGC-1α.	250–500 mg/day NMN or NR; morning dosing preferred. ⚠ Pediatric Advisory: Dosing range shown reflects adult literature. Pediatric dosing not established. Do not extrapolate from adult doses. Pediatric use only under direct medical supervision with NAD¹ metabolite monitoring where possible.	Early Human
NAD¹ / PARP Inhibition	Niacinamide (B3) Conditional adjunct — dose ceiling critical	Enters NAD¹ synthesis via the NAMPT salvage pathway — distinct from NMN/NR’s NRK pathway. Primary mechanistic value here is as a PARP inhibitor: PARP enzymes consume NAD¹ during DNA damage repair, and under chronic oxidative stress PARP hyperactivation is a major NAD¹ drain. Niacinamide blocks this consumption, preserving NAD¹ for SIRT1. Also has independent NF-κB suppression. Wave 1 role: Plug the PARP drain before filling the NAD¹ tank with NMN/NR. Critical: niacinamide is a SIRT1 reaction byproduct — excess niacinamide inhibits SIRT1 via product feedback. The 500 mg dose ceiling is a hard boundary protecting the central axis of this protocol.	250–500 mg/day. Separate from NMN/NR by 2–4 hours. ⚠ Dose Ceiling — 500 mg/day Maximum Above this threshold niacinamide accumulates as a SIRT1 reaction byproduct and directly inhibits SIRT1 — the opposite of the protocol goal. High-dose niacinamide (>1g) negates NMN/NR and resveratrol in the same stack.	Early Human
SIRT1 Activation	Resveratrol trans-Resveratrol preferred	Allosteric SIRT1 activator (STAC); deacetylates NF-κB p65 subunit → reduces IL-6, TNF-α, IL-1β; activates PGC-1α → mitochondrial biogenesis; supports CREB co-activation. ASD animal model data shows reduced oxidative stress and improved social behavior.	100–500 mg/day; take with fat for absorption; pterostilbene (50–150 mg) offers better bioavailability and BBB penetration.	Early Human
SIRT1 Activation	Pterostilbene Resveratrol analog	Dimethylated resveratrol analog with superior oral bioavailability (~80% vs ~20%) and greater lipophilicity for CNS penetration. SIRT1 activation, NF-κB suppression, mitochondrial support. Reduces neuroinflammation in animal models.	50–150 mg/day; may be preferred over resveratrol for CNS targeting.	Animal / Preclinical
SIRT1 Activation	Fisetin Flavonoid / Senolytic	Polyphenol with SIRT1-activating and senolytic properties; reduces senescent glial cells; activates AMPK/SIRT1 axis; enhances mitochondrial biogenesis and antioxidant defense; BDNF upregulation in animal models.	100–500 mg/day; pulsed dosing (2–3 days/month) used in senolytic protocols; pediatric data absent.	Animal / Preclinical
SST Reduction	Stress / Metabolic Load Reduction Lifestyle, sleep, circadian rhythm	SST release is triggered by chronic stress, metabolic strain, and inflammatory signaling. Reducing these upstream drivers lowers SST tone → partially restores AC/cAMP/PKA/CREB signaling. Addresses the SST node directly without pharmacological intervention.	Sleep optimization, circadian regularity, reducing sensory/inflammatory triggers, cortisol management. Foundational before any supplement protocol.	Human RCT
SST / cAMP Node	Forskolin Coleus forskohlii extract	Direct adenylyl cyclase activator → raises intracellular cAMP independently of SST inhibition → activates PKA → CREB phosphorylation → BDNF transcription. Directly opposes SST-mediated AC suppression. Enhanced learning and synaptic plasticity in animal models.	Low-dose 5–10 mg/day standardized forskolin. Animal data strong; human ASD trials absent. ⚠ Hemodynamic Risk — Practitioner Supervision Required Forskolin is the only compound in this protocol with direct hemodynamic risk. As a potent adenylyl cyclase activator it lowers systemic vascular resistance and reduces blood pressure via cAMP-mediated vasodilation. Contraindicated in: Cardiac conditions (arrhythmia, heart failure, structural disease) · Hypotension · Concurrent antihypertensives or vasodilators. Required before use: Cardiovascular assessment · Blood pressure monitoring during titration · Prescribing physician oversight for all pediatric use. For parents: Never start forskolin without a doctor first checking your child's heart and blood pressure — and with ongoing monitoring throughout use.	Animal / Preclinical
NF-κB / Microglia	Luteolin Flavonoid — mast cell / microglial / CD38	Potent NF-κB and AP-1 inhibitor; suppresses mast cell degranulation and microglial pro-inflammatory cytokine release (IL-6, TNF-α); directly suppresses SPARC expression in astrocytes; may support hevin/glypican balance. CD38 inhibition: luteolin reduces CD38 expression and activity in immune-activated cells — CD38 is the primary NAD¹ consumer during immune activation, competing directly with SIRT1 for the same substrate. This gives luteolin a dual Wave 1 role: anti-inflammatory AND NAD¹ drain reduction. Two clinical studies in ASD children show reduced TNF and IL-6 and improved irritability scores.	100–400 mg/day luteolin (or luteolin + quercetin formulation); take with fat. Pediatric RCT data available.	Human RCT
NF-κB / Oxidative	Curcumin Phospholipid complex preferred	NF-κB inhibitor; Nrf2/HO-1 activator; reduces TNF-α, IL-6, MMP-9; mitochondrial protective; modulates gut microbiota. ASD animal models show reduced oxidative-nitrosative stress and improved social behaviors. Small human ASD trials show improvement in irritability and hyperactivity.	500–1500 mg/day as phospholipid complex (e.g., Meriva) or nanoparticle form for bioavailability; poor absorption of standard curcumin.	Early Human
ERβ / AC/cAMP / SST axis	Genistein Soy isoflavone / selective ERβ agonist	Mechanistically unique in this protocol. Genistein binds ERβ with 7–8× higher affinity than ERα — and ERβ activation directly stimulates adenylyl cyclase (AC) → cAMP → PKA → CREB, the exact pathway SST suppresses from the opposite direction. This gives genistein a complementary angle no other compound in the suite shares: it works to reopen the AC/cAMP axis from the estrogen receptor side while SST-reducing interventions relieve the somatostatin brake. This mechanism is also the leading candidate for why the ASD sex ratio skews ~4:1 male-to-female — females have endogenous estrogen maintaining basal ERβ → cAMP tone that males lack. Additional mechanisms: NF-κB suppression via GPER → adenylate cyclase (quiets M1 microglia); direct cortical neuron and astrocyte protection from oxidative stress via Bcl-2 preservation and Nrf2/HO-1 activation; SIRT1 activation; mitochondrial ETC complex restoration. In a propionic acid ASD rat model (Kumar et al., 2024), genistein restored AC, cAMP, CREB, and PKA levels, reduced neuroinflammation, normalized neurotransmitter balance, and improved all behavioral outcomes measured. Developmental timing note: Evidence above applies to therapeutic use in older children and adults. Neonatal/infant dietary genistein exposure (soy formula) represents a different context and warrants separate clinical consideration.	Therapeutic range not established in human ASD trials. Animal model efficacy at 40–80 mg/kg. Human phytoestrogen literature typically references 20–60 mg/day dietary equivalents. Use only under clinical supervision given estrogenic activity — particularly relevant in males and prepubertal children. Avoid in infants.	Animal / Preclinical
Omega-3 / Microglia	EPA/DHA — Omega-3 High-EPA formulation preferred	Suppresses NF-κB-driven neuroinflammation; promotes microglial M2 (anti-inflammatory) phenotype; supports membrane fluidity for receptor function; improves BDNF levels; reduces IL-6, IL-1β. Meta-analyses show modest but consistent benefit on irritability and hyperactivity in ASD.	1–3 g/day EPA+DHA; high-EPA formulations (EPA:DHA ≥2:1) preferred for neuroinflammation. Well-tolerated in children.	Human RCT
FOXO / Antioxidant	N-Acetylcysteine (NAC) Glutathione precursor	Replenishes glutathione (GSH) — primary antioxidant depleted under FOXO suppression; modulates glutamate via cystine-glutamate antiporter (mGluR pathway); dampens microglial ROS; anti-inflammatory. RCT in ASD children showed significant reduction in irritability vs placebo.	600–1200 mg/day in divided doses; well-studied in ASD children; generally well-tolerated.	Human RCT
Nrf2 / Antioxidant	Sulforaphane Broccoli sprout extract	Activates Nrf2 → upregulates antioxidant and cytoprotective genes (HO-1, NQO1, GSH synthesis); modulates neuroinflammatory pathways; mitochondrial protective. Placebo-controlled trial in ASD adolescents showed clinically meaningful improvements in ABC and SRS subscales; scores worsened after discontinuation.	50–150 µmol/day sulforaphane (standardized sprout extract); broccoli sprout powder variable — standardized extract preferred.	Human RCT
Mitochondria / PGC-1α	CoQ10 / Ubiquinol Ubiquinol form preferred	Essential electron transport chain cofactor; supports Complex I and III activity; reduces mitochondrial ROS; improves ATP generation. Pilot studies in ASD show reduced oxidative stress markers. Ubiquinol (reduced form) preferred for absorption.	100–400 mg/day ubiquinol; take with fat; well-tolerated.	Early Human
Mitochondria / ATP	Magnesium Glycinate Also: Mg-Threonate for CNS	Required cofactor for 300+ enzymatic reactions including ATP synthesis; NMDA receptor modulator reducing excitotoxic Ca²¹ influx; supports GABAergic tone; reduces hyperexcitability and sensory sensitivity. One of the most consistently supported supplements in ASD with RCT data.	Mg glycinate 100–400 mg elemental/day; Mg-Threonate 1.5–2 g/day for CNS targeting; magnesium B6 combination also has RCT evidence in ASD.	Human RCT
E/I Balance / SST Reduction	L-Theanine Green tea amino acid	Increases GABA and glycine, shifting E/I balance toward inhibition without sedation. Glycine co-agonism at NMDA receptors supports magnesium channel block efficacy — reducing excitatory drive to open NMDA channels while magnesium blocks them. Simultaneously modulates AMPA receptor trafficking, reducing excitatory tone. Direct cortisol blunting feeds into the SST reduction arm. Synergistic with magnesium: complementary mechanisms on the same excitotoxicity target.	100–200 mg/day. Take with magnesium for synergistic E/I effect; bedtime dosing a natural pairing. Well-tolerated across age ranges; no significant contraindications at standard doses.	Early Human
Gut — Barrier / Dysbiosis	Clostridium butyricum Butyrate-producing probiotic	Produces butyrate → HDAC inhibition → epigenetic regulation; reduces gut inflammation and intestinal permeability; supports regulatory T-cell function; modulates microglial development; improves BDNF expression; directly opposes propionate excess. Emerging human studies in ASD show GI and behavioral improvements.	1–2 billion CFU/day; typically 1–2 capsules; refrigeration required for most preparations.	Early Human
Gut — Barrier / LPS / Immune	Saccharomyces boulardii Probiotic yeast — antibiotic-resilient	Mechanistically distinct from C. butyricum. Stimulates secretory IgA (sIgA), strengthening mucosal immune defense against LPS-producing bacteria. Competitive exclusion of pathogens. Reduces intestinal permeability via tight junction upregulation (claudin-3, ZO-1). Reduces gut-derived LPS translocation through a non-butyrate pathway — complementing C. butyricum’s HDAC mechanism. Reduces IL-8 and TNF-α in intestinal epithelium. Unique advantage: antibiotic-resilient — continues working during antibiotic courses when bacterial probiotics must be paused.	5–10 billion CFU/day. No refrigeration required. Take concurrently with C. butyricum. Can be continued during antibiotic courses unlike bacterial probiotics.	Early Human
Gut — Butyrate / CREB	Sodium Butyrate Short-chain fatty acid supplement	Direct butyrate supplementation; HDAC inhibitor → increases histone acetylation, BDNF expression, and synaptic plasticity gene transcription; supports gut barrier integrity; improves microglial maturation; social behavior improvements in ASD animal models. Targets Stage 4 (gut-brain) and Stage 6 (CREB/learning).	300–600 mg sodium butyrate/day in divided doses; enteric-coated forms reduce odor; animal data strong, human ASD trials emerging.	Animal / Preclinical
Gut — E/I Balance	Melatonin Sleep + circadian + antioxidant	Most consistently effective ASD intervention for sleep; antioxidant and mitochondrial-supportive properties; reduces nocturnal cortisol → indirectly lowers SST release; improves circadian regularity. Systematic review and meta-analysis confirm efficacy for sleep in ASD. Downstream: improved sleep reduces inflammatory load across multiple cascade nodes.	0.5–5 mg at bedtime; low-dose (0.5–1 mg) often sufficient; immediate-release preferred for sleep onset; extended-release for maintenance.	Human RCT
SIRT1 / Senescent Glia	Synthetic SIRT1 Activators SRT2104, SRT1720 (research-grade)	Potent STACs with >1000x greater SIRT1 activation than resveratrol; improve mitochondrial biogenesis; reduce neuroinflammation. Early human trials for metabolic and aging conditions show safety and efficacy. No ASD-specific trials yet. High mechanistic relevance to cascade Nodes 3 and 3A–D.	Research-grade; not commercially available for clinical use. SRT2104: 0.5–2 g/day in adult metabolic trials. ASD application requires clinical trial design.	Mechanistically Plausible
Synapse Proteins	Hevin / SPARC Modulation Preclinical target	Therapeutic strategies to directly increase hevin/glypican signaling or suppress SPARC at the astrocyte level would restore the synaptogenic protein balance inverted in ASD. No approved therapeutics yet; indirect support via luteolin (SPARC suppression) and NF-κB inhibition offers partial benefit.	Preclinical only. Indirect approaches: luteolin for SPARC suppression; NF-κB inhibitors to reduce A1 astrocyte conversion. Direct hevin modulation remains a research target.	Mechanistically Plausible

Parent & Caregiver View — Plain Language Summary

Magnesium

Helps calm overactive nerve signals and supports energy production in brain cells. One of the most studied supplements in autism research with evidence for reducing sensory sensitivity and hyperexcitability.

Sensory sensitivitySleepNerve signaling

Generally well-tolerated in children. Magnesium glycinate is gentle on the stomach. Always discuss dosing with your doctor.

Melatonin

Helps regulate sleep timing, which is disrupted in most autistic children. Better sleep also reduces stress hormones overnight, which indirectly lowers inflammation across the whole cascade.

Sleep onsetSleep maintenanceStress hormones

Well studied in autism. Start low (0.5 mg). Discuss timing and dose with your doctor, especially for younger children.

NAC (N-Acetylcysteine)

Helps the body make glutathione — the brain's main antioxidant defense, which is often depleted in autism. Also helps calm overactive glutamate signaling. A randomized trial in autistic children showed reduced irritability.

Antioxidant defenseIrritabilityInflammation

Well-tolerated. May cause mild GI upset initially. Pediatric RCT data available. Use under practitioner supervision.

Omega-3 (EPA/DHA)

Fish oil helps calm the brain's immune cells (microglia) and supports healthy brain cell membranes. Meta-analyses show modest consistent benefit for irritability and hyperactivity in autism. High-EPA formulations work best for brain inflammation.

IrritabilityHyperactivityBrain inflammation

Very safe in children. Choose a high-quality, third-party tested fish oil. 1–2 g EPA+DHA per day is a typical starting range.

Luteolin

A natural flavonoid found in celery, parsley, and chamomile that calms overactive immune cells in the brain. Two clinical studies specifically in autistic children showed reduced inflammatory markers and improved irritability scores.

NeuroinflammationIrritabilityImmune balance

Pediatric clinical trial data available. Often combined with quercetin. Take with food containing fat. Discuss with your doctor before starting.

Sulforaphane

A compound from broccoli sprouts that activates the body's own antioxidant system. A placebo-controlled trial in autistic adolescents showed meaningful improvements in behavior and social scores — and scores worsened when it was stopped.

Antioxidant systemBehaviorSocial scores

Choose standardized extract, not plain broccoli powder (highly variable). Human trial data available. Discuss with your doctor.

Resveratrol / Pterostilbene

Plant compounds (from grapes and blueberries) that activate SIRT1 — one of the two central regulatory proteins in the autism cascade. They help reduce brain inflammation, support mitochondria, and improve antioxidant levels. Pterostilbene reaches the brain more easily.

SIRT1 activationInflammationMitochondria

Early human evidence in autism. Pediatric dosing not firmly established. Use only under practitioner guidance.

Clostridium butyricum

A beneficial gut bacteria that produces butyrate — a short-chain fatty acid that reduces gut inflammation, heals the gut lining, and helps regulate the brain's immune cells. Emerging human studies in autism show GI and behavioral improvements.

Gut healthBrain immune cellsGut-brain axis

Generally well-tolerated probiotic. Requires refrigeration. Discuss with your doctor, especially if your child has immune conditions.

CoQ10 (Ubiquinol)

Supports the energy-producing parts of cells (mitochondria), which are often underperforming in autism. Ubiquinol is the active, better-absorbed form. Pilot studies in autism show reduced oxidative stress markers.

Mitochondrial energyOxidative stressCell health

Well-tolerated. Take with a meal containing fat. Ubiquinol preferred over ubiquinone for absorption in children.

L-Theanine

An amino acid from green tea that works as a calming partner with magnesium. Magnesium blocks overactive NMDA channels in the brain; L-theanine reduces the excitatory signals that try to force those channels open. Together they address E/I imbalance from two complementary directions — without sedation. Good evidence for anxiety and attention; safe across age ranges.

E/I BalanceSST ReductionNMDAAMPA

Pairs best with magnesium. Take both together at bedtime. No significant contraindications at standard doses.

Saccharomyces boulardii

A beneficial yeast (not a bacterium) that helps seal the gut lining and crowds out harmful bacteria that release inflammatory toxins. Works differently from C. butyricum — they complement each other. Most important feature: it keeps working even during antibiotic treatment, when regular probiotics are wiped out.

Gut BarriersIgALPS ReductionAntibiotic-Safe

No refrigeration needed. Safe during antibiotics. Take alongside C. butyricum.

Niacinamide (B3)

A form of Vitamin B3 that reduces the “leak” in the NAD¹ system. While NMN/NR refills the NAD¹ tank, niacinamide plugs a drain — blocking the PARP enzyme that wastes NAD¹ during constant cellular repair under chronic inflammation. Important: only the low dose works this way; high doses have the opposite effect.

NAD¹ ConservationPARP InhibitionNF-κB

⚠ Hard dose ceiling: 250–500 mg/day only. Higher doses inhibit SIRT1 — the central node this protocol targets. Separate from NMN/NR by 2–4 hours.

NMN / NR (NAD¹ precursors)

Help restore NAD¹, the fuel that powers SIRT1 — one of the two key regulatory proteins in the autism cascade. Inflammation from autism biology depletes NAD¹, which shuts down SIRT1 and allows inflammation to spiral. Restoring NAD¹ is a foundational upstream step.

SIRT1 fuelEnergy metabolismInflammation control

Early human evidence in adults; pediatric dosing not established. Use only under practitioner guidance. Do not use without professional oversight in children.

Fisetin

A flavonoid found in strawberries that activates SIRT1 and helps clear out old, damaged brain cells (senescent glia) that contribute to chronic inflammation. Strong animal model evidence; human autism trials not yet conducted.

SIRT1 activationGlial healthInflammation

Animal model data only in ASD context. Discuss with your practitioner before use in children. Promising but not yet clinically validated in autism.

Curcumin

The active compound in turmeric; reduces brain inflammation and supports antioxidant systems. Animal ASD models show strong effects; small human studies suggest benefit for irritability and hyperactivity. Poor absorption — choose a formulated version (phospholipid complex or nanoparticle).

NeuroinflammationIrritabilityGut microbiome

Standard curcumin powder has very poor absorption. Use only formulated preparations. Small human studies in ASD available; discuss with your doctor.

Genistein

A natural compound found in soy and legumes that mimics estrogen in the brain by activating estrogen receptor beta (ERβ) — which directly switches on the same learning and plasticity signaling pathway (AC → cAMP → CREB) that the cascade shuts down. This makes genistein unique in the protocol: most compounds work to reduce inflammation or restore SIRT1, but genistein works to reopen the plasticity pathway from a completely different angle. It also protects brain cells from oxidative damage and quiets microglial inflammation. Researchers believe this estrogen-related mechanism may partly explain why autism affects boys far more than girls — girls have natural estrogen keeping this pathway open. A 2024 study using an autism rat model showed genistein restored these signaling pathways and improved behavioral outcomes.

Plasticity signalingNeuroinflammationBrain cell protectionAntioxidant

Genistein is estrogenic — it affects hormone-sensitive systems. This makes clinical supervision essential, especially in boys and prepubertal children. Avoid in infants. Human ASD dosing trials have not yet been conducted. Do not use independently — discuss with your practitioner before considering this compound.

Sodium Butyrate

Butyrate is a short-chain fatty acid naturally produced in the gut by beneficial bacteria — it is one of the key signals the gut sends to the brain and immune system. Sodium butyrate is a supplemental form that delivers butyrate directly. It works in two important ways: it supports the gut lining and helps restore barrier integrity, and it acts on gene expression in the brain to increase BDNF — the growth factor that helps neurons form new connections and supports learning. Animal models of autism show improvements in social behavior and synaptic plasticity. It also supports the shift toward a healthier gut microbiome. C. butyricum (also in this protocol) produces butyrate naturally in the gut — the two approaches are complementary.

Gut barrier repairBDNF / learningSynaptic plasticityMicrobiome support

Generally well tolerated. Enteric-coated forms reduce the characteristic odor. Animal data strong; human ASD trials are emerging but limited. Use under practitioner guidance, especially in children.

Forskolin ⚠

Forskolin directly activates adenylyl cyclase — the enzyme that produces cAMP, the key signaling molecule that somatostatin suppresses in the cascade. This means forskolin can push the AC → cAMP → CREB learning pathway open from the inside, independently of other interventions. In animal models it supports synaptic plasticity and neural circuit function. It is one of the most mechanistically targeted compounds in the protocol for the SST suppression problem.

AC/cAMP activationSST brake reliefSynaptic plasticityCREB/BDNF support

⚠ Medical supervision required before and during use. Forskolin is the only compound in this protocol with direct cardiovascular risk. As a potent adenylyl cyclase activator it lowers blood pressure by relaxing blood vessels. This can be dangerous in children with heart conditions, low blood pressure, or those taking blood pressure medications.

Do not start without: A cardiovascular assessment by your doctor · Blood pressure checked before and during use · Prescribing physician oversight for all pediatric use.

Do not use in children with: Any heart condition · Low blood pressure · Concurrent blood pressure or heart medications.